Drug Trial Radar · NCT06857227
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Mar 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
GNC-038Drug
Administration by intravenous infusion. Once a week (IV, QW), twice in total.
PlaceboDrug
The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to approximately 28 days
- Phase Ia: Maximum tolerated dose (MTD) or Maximum administered dose (MAD)Time frame: Up to approximately 28 days
- Phase Ia: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
- Phase Ia: CmaxTime frame: Up to approximately 24 months
- Phase Ia: TmaxTime frame: Up to approximately 24 months
- Phase Ia: T1/2Time frame: Up to approximately 24 months
- Phase Ia: AUC0-tTime frame: Up to approximately 24 months
- Phase Ia: CL (Clearance)Time frame: Up to approximately 24 months
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
- Phase Ib: Proportion of patients meeting ACR20 remission criteriaTime frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.